stockrowEvogene Ltd.
EVGN Healthcare Biotechnology
Evogene Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $3.9 million, down 54.7% from fiscal 2024.
- Revenue
- −35.0%
- EPS
- +77.4%
- Free cash flow
- +17.7%
Quarter to June 2026, against a year earlier
Follow EVGN
Alert me
Evogene Ltd. (EVGN) EV/Sales
As of 6 November 2026, Evogene Ltd. (EVGN) trades at a EV/Sales of −3.6×. Over the past ten years it has ranged from −36.6× (March 2020) to 223× (February 2021); the current reading is higher than 14% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −1.1× | — |
| FY2024 | −0.5× | — |
| FY2023 | 1.6× | — |
| FY2022 | −3.3× | — |
| FY2021 | 13.4× | (83.46%) |
| FY2020 | 80.9× | — |
| FY2019 | −10.3× | — |
| FY2018 | −2.0× | — |
| FY2017 | 5.1× | (18.44%) |
| FY2016 | 6.3× | (29.74%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −2.4× | — |
| Mar 2026 | −3.0× | — |
| Dec 2025 | −1.1× | — |
| Sep 2025 | −1.3× | — |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AIM AIM ImmunoTech Inc. compare | −71.4× |
| APRE Aprea Therapeutics, Inc. compare | −34.8× |
| EVGN Evogene Ltd. | −3.6× |
| CRIS Curis, Inc. compare | −0.3× |
| ENVB Enveric Biosciences, Inc. compare | −0.1× |
| CNSP CNS Pharmaceuticals, Inc. compare | n/m |
| FBLG FibroBiologics Inc. compare | n/m |
| XCUR Exicure, Inc. compare | 0.2× |
| ORGS Orgenesis Inc. compare | 16.9× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)